Redeye comments on Kenneth Dart's increased ownership in Evolution, having formally exceeded 30% of ...
Heliospectra's Board has resolved to file for bankruptcy, with the petition submitted to Gothenburg ...
Friday's Q2/H1 figures once again underlined the strength of ATOSS' recurring revenue engine, while ...
We downgrade our full-year 2026 EBIT forecast by 10% due to the profit warning issued on 24 July.
Redeye updates its estimates and valuation following Momentum Group’s Q2 2026 report.
Ahead of Gofore’s Q2, our estimates are trimmed slightly due to its exit of the product design busin...
Q2: Sales of EUR 45m (36m), adj. EBIT of -EUR 1.1m (-0.
Redeye comments on Alligator Bioscience’s recently announced strategic pivot and accompanying rights...
Incap confirmed its FY2026 net sales growth guidance but downgraded its EBITA guidance.
Redeye updates its estimates and valuation after Lifco’s Q2 2026 report.
Genovis' Q2 came in showing a minor deviation on sales (-5% vs REe) while painting a positive pictur...
Redeye comments on the news of the CEO transition at Elicera and consolidation in Uppsala.
Enviro's second quarter was eventful from a broader news-flow perspective, although the Q2 report it...
Bred tillväxt och stark underliggande resultatutveckling Bruttoresultatet ökade med 17,7 % till 60,...
Stille's Q2 painted a picture of continued sales momentum (+8% vs.
* Another strong quarter for P&M orders * Sales EUR 44.
Vaxxa redovisade ett starkt omsättningslyft i Q2 2026, där nettoomsättningen ökade med 57 % till 29,...
Redeye comments on CLS’s rights issue announcement and updates its valuation of the company accordin...
Redeye retains its positive view of Hansa Biopharma following a transformative second quarter.
Genovis Q2 2026 was characterised by strategic expansion following the KPL acquisition and encouragi...
